The data is collected in a period from 01/01/2023 to 31/03/2023.
Q1. In the last 3 months, how many patients have been initiated* on the following agents for the treatment of melanoma?
|
Ipilimumab (monotherapy)
|
0
|
|
Nivolumab (monotherapy)
|
0
|
|
Nivolumab AND Ipilimumab (combination)
|
0
|
|
Pembrolizumab
|
0
|
|
Any Targeted Therapy (Dabrafenib /Dabrafenib AND Trametinib /Encorafenib AND Binimetinib /Trametinib /Vemurafenib /Vemurafenib AND Cobimetinib)
|
0
|
|
Other active systemic anti-cancer therapy
|
0
|
Melanoma is treated at the cancer centre (LTHTR). We do not treat at ELHT and no data available.
*Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs
that are part of the named regimen.
Q2. In the last 3 months, how many patients have been initiated* on the following agents for the treatment of Renal
Cell Carcinoma?
We have used the following diagnoses to obtain these figures:
- Renal cell carcinoma
- Malignant neoplasm of unspecified kidney, except renal pelvis
|
Nivolumab (monotherapy)
|
0
|
|
sNivolumab + Ipilimumab
|
<5
|
|
Nivolumab + Cabozantinib
|
0
|
|
Avelumab + Axitinib
|
<5
|
*Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs
that are part of the named regimen.
Q3. In the past 3 months, how many patients have been initiated* on the following agents for treatment of Oesophageal Cancer:
IQemo doesn't differentiate well for upper gastrointestinal cancer.
We have used the following diagnoses to obtain these figures
- Oesophagus
- Oesophagus, Gastro-oesophageal junction
- Gastro-oesophageal junction
- Gastro-oesophageal cancer
- Gastro-intestinal stromal tumor
- Gastro-oesophageal junction, Gastro-Oesophageal cancer
|
Nivolumab monotherapy or in combination with Ipilimumab
|
<5
|
|
Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidene (5-Fluorouracil or Capecitabine)
|
0
|
|
Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidene (5-Fluorouracil or Capecitabine)
|
<5
|
*Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that
are part of the named regimen.
